G. V. Papatheodoridis Et Al. , "Timing of hepatocellular carcinoma HCC developmentand predictability of a modified PAGE B risk score incaucasian chronic hepatitis B CHB patients treated withentecavir ETV or tenofovir TDF," AASLD 2015 , 2014
Papatheodoridis, G. V. Et Al. 2014. Timing of hepatocellular carcinoma HCC developmentand predictability of a modified PAGE B risk score incaucasian chronic hepatitis B CHB patients treated withentecavir ETV or tenofovir TDF. AASLD 2015 .
Papatheodoridis, G. V., Dalekos, G. N., Sypsa, V., YURTAYDIN, S. C., Buti, M., Goulis, I., ... Chi, H.(2014). Timing of hepatocellular carcinoma HCC developmentand predictability of a modified PAGE B risk score incaucasian chronic hepatitis B CHB patients treated withentecavir ETV or tenofovir TDF . AASLD 2015
Papatheodoridis, ONUR Et Al. "Timing of hepatocellular carcinoma HCC developmentand predictability of a modified PAGE B risk score incaucasian chronic hepatitis B CHB patients treated withentecavir ETV or tenofovir TDF," AASLD 2015, 2014
Papatheodoridis, ONUR Et Al. "Timing of hepatocellular carcinoma HCC developmentand predictability of a modified PAGE B risk score incaucasian chronic hepatitis B CHB patients treated withentecavir ETV or tenofovir TDF." AASLD 2015 , 2014
Papatheodoridis, G. V. Et Al. (2014) . "Timing of hepatocellular carcinoma HCC developmentand predictability of a modified PAGE B risk score incaucasian chronic hepatitis B CHB patients treated withentecavir ETV or tenofovir TDF." AASLD 2015 .
@conferencepaper{conferencepaper, author={ONUR KESKİN Et Al. }, title={Timing of hepatocellular carcinoma HCC developmentand predictability of a modified PAGE B risk score incaucasian chronic hepatitis B CHB patients treated withentecavir ETV or tenofovir TDF}, congress name={AASLD 2015}, city={}, country={}, year={2014}}